Platelet Reactivity In Patients With Nuisance Bleeding On A Thienopyridine
NCT ID: NCT01152229
Last Updated: 2011-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
300 participants
OBSERVATIONAL
2010-04-30
2011-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Association Between Platelet Reactivity and Bleeding Risk in Adult ITP
NCT03377439
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
NCT06291415
A Clinical Trial of Chidamide in the Management of Refractory ITP
NCT03838354
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP
NCT03102593
Platelet Glycoproteins in Inherited Thrombocytopathy: Association With Aggregation Studies and Bleeding Severity
NCT03648190
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
nuisance bleeding
No interventions assigned to this group
alarming bleeding
No interventions assigned to this group
maintenance therapy
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Underwent PCI within the last year
* Taking maintenance dose of clopidogrel 75 mg once a day or prasugrel 10 mg once a day for at least five days
Exclusion Criteria
* Use of a glycoprotein (GP)IIb/IIIa inhibitor within 8 hours of the blood draw.
* Patient known to be pregnant or lactating
* Patient with known history of anemia, thrombocytopenia, bleeding disorder, or currently active bleeding
* On warfarin therapy at the time of blood draw
* Known blood transfusion within the preceding 10 days of the blood draw
* Patients treated with non-steroidal anti-inflammatory drugs (NSAIDS, not to include aspirin) within the previous 5 days
* Any significant medical condition that, in the investigator's opinion, may interfere with the patient's optimal participation in the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medstar Health Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cardiovascular Research Institute/ Medstar Health Research Institute
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Gaglia, MD
Role: PRINCIPAL_INVESTIGATOR
Cardiovascular Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Washington Hospital Center
Washington D.C., District of Columbia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PLACID
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.